Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments

This book provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It discusses glutamate as a neurotransmitter, its receptors, and transporters, and their interplay with other neurotransmitters and neurotrophic factors. The book covers a range of CNS diseases, including ischemic stroke, chronic stress, major depressive disorder, bipolar disorder, autism spectrum disorders, posttraumatic stress disorder, Alzheimer's dementia, schizophrenia, impulsive aggression, substance use disorders, ALS, chronic pain, multiple sclerosis, Parkinson's disease, attention deficit hyperactivity disorder, migraine, epilepsy, and anxiety disorders. It also includes an overview of glutamatergic treatments available on the market and those in pharmaceutical drug development pipelines. The book is intended for neurology and psychiatry specialists, neuroscientists, neuropharmacologists, pharmaceutical industry professionals, academics, and clinicians working with psychiatric and neurological patients.

Format: Hardback
Length: 600 pages
Publication date: 11 April 2022
Publisher: Springer Nature Switzerland AG

This comprehensive volume delves into the latest advancements in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. Drawing upon the latest findings in glutamate neurobiology, it provides invaluable insights into the application of translational principles in neuroscience drug discovery and development.

In the chapters that follow, glutamate, as a neurotransmitter, its receptors, and transporters, are explored in the context of specific and highly prevalent CNS diseases. The most up-to-date and detailed information is provided on a range of conditions, including Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer's Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy, and Anxiety disorders.

Furthermore, the book offers an extensive overview of glutamatergic treatments that are already available on the market, as well as those that are currently in the pharmaceutical drug development pipeline. The primary audience for this book includes neurology and psychiatry specialists, residents, neuroscientists, neuropharmacologists, pharmaceutical industry professionals, clinical research organization professionals, academics, and clinicians who work with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. Additionally, this book will appeal to psychiatry and neurology subspecialists and clinicians who operate in neuroscience labs seeking a concise yet comprehensive overview of contemporary evidence-based approaches to glutamate signaling in the treatment of psychiatric and neurological disorders.

Weight: 1112g
Dimension: 235 x 155 (mm)
ISBN-13: 9783030874797
Edition number: 1st ed. 2022